Search Results

You are looking at 81 - 90 of 487 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Kevin Zhang, Ladan Navari, Amy Li, Sandy Lee, Yevgeniya Gokun, Min-Jeong Cho, Roman Skoracki, and Ko Un Park

.2% PLVB vs 31.9% without PLVB) but completed fewer post-op PT appointments (p<0.0001) (Table1). Patients who received neoadjuvant chemotherapy or adjuvant radiation were more likely to have a pre-op PT appointment, while those who received either adjuvant

Full access

/18/14 NCCN Guidelines® Insights: Metastatic Colon Cancer, Version 3.2013 Expiration Date: 2/18/14 Using Multigene Tests to Select Treatment for Early-Stage Breast Cancer Expiration Date: 2/18/14 CASE REPORT: Adjuvant Chemotherapy Decisions in Clinical

Full access

Early-Stage Breast Cancer Expiration Date: 2/18/14 CASE REPORT: Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations

Full access

A. Dimitrios Colevas, Sue S. Yom, David G. Pfister, Sharon Spencer, David Adelstein, Douglas Adkins, David M. Brizel, Barbara Burtness, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, David W. Eisele, Moon Fenton, Robert L. Foote, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Wesley L. Hicks Jr, Ying J. Hitchcock, Antonio Jimeno, Debra Leizman, Ellie Maghami, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, James Rocco, Cristina P. Rodriguez, Jatin P. Shah, Randal S. Weber, Matthew Witek, Frank Worden, Weining Zhen, Jennifer L. Burns, and Susan D. Darlow

in any form without the express written permission of NCCN®. randomized trial from China comparing concurrent cisplatin/RT with (or without) adjuvant cisplatin/5-FU showed that adjuvant chemotherapy did not significantly improve survival following CRT

Full access

Kushal Naha, Abdulmateen Adebiyi, Praveen Rao, and Christos Papageorgiou

positive node negative breast cancers <1 cm often do not need adjuvant chemotherapy while those with stage III disease typically do. Unfortunately, most cases of breast cancer fall between these two extremes and require additional genomics and

Full access

Lindsay A. Gil, Mariam F. Eskander, Samilia Obeng-Gyasi, Bridget A. Oppong, Yaming Li, and Allan Tsung

receiving fragmented care (treatment at multiple facilities) and its implications on receipt of GCC. Methods: The National Cancer Database (NCDB) 2006-2016 was queried for patients with pancreatic adenocarcinoma who underwent resection and adjuvant

Full access

Peter E. Clark, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, A. Karim Kader, Adam S. Kibel, Timothy M. Kuzel, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, and Courtney Smith

of adjuvant systemic chemotherapy in invasive bladder cancer. Studies have shown that adjuvant chemotherapy may delay recurrences and improve OS, 41 – 43 but no randomized comparisons of adequate sample size have definitively shown a survival benefit

Full access

Jagar Jasem, Christine M. Fisher, Arya Amini, Elena Shagisultanova, Rachel Rabinovitch, Virginia F. Borges, Anthony Elias, and Peter Kabos

Background Adjuvant chemotherapy was once considered the standard of care for patients with primary breast cancer with tumors >1 cm regardless of axillary lymph node involvement. 1 – 3 However, given disease recurrence rates of <20% by 10

Full access

Lucy X. Ma, Elan D. Panov, Michael J. Allen, Gail E. Darling, Jonathan C. Yeung, Carol J. Swallow, Savtaj S. Brar, Rebecca K. Wong, Patrick Veit-Haibach, Sangeetha N. Kalimuthu, Eric X. Chen, Raymond W. Jang, and Elena Elimova

standardized approach and notable geographic variation in treatment exists. Up-front surgery with adjuvant chemotherapy is favored in Asian countries, whereas neoadjuvant or perioperative treatment is preferred in Europe and North America. 8 – 11 The

Full access

Betsy L. Althaus

Jones RJ Davidson NE . Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support (letter) . J Clin Oncol 2006 ; 24 : 2392 – 2394 . 16. Brusamolino E Rusconi C Montalbetti L . Dose-dense R